Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Azacitidine for AML with Persistent or Reappearing MRD (VERDI)
NCT06668558Phase 2Active, not recruiting
- Start
- Dec 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, azacitidine in acute myeloid leukemia (AML). Started Dec 2024; status: active, not recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06668558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668558.